HOME >> MEDICINE >> NEWS
NIAID Renews Funding For Multicenter AIDS Cohort Study

The National Institute of Allergy and Infectious Diseases (NIAID) has awarded five-year grants to continue the work of the Multicenter AIDS Cohort Study (MACS), the largest continually followed group of HIV-infected or at-risk individuals in the world. Approximately $6 million in first-year funding will be distributed among MACS research centers at The Johns Hopkins University; the University of Pittsburgh; Northwestern University; and the University of California at Los Angeles.

"We're delighted to continue supporting the MACS," says Anthony S. Fauci, M.D., director of NIAID. "This study has been instrumental in advancing our understanding of the pathogenesis and natural history of HIV disease, and thus has important implications for therapy."

The MACS has enrolled more than 5,600 individuals since 1984. Currently, there are 1,775 active enrollees, of which about 38 percent are HIV-positive. A total of 1,237 MACS volunteers have died of AIDS.

MACS data have contributed to nearly 700 publications in medical and scientific journals. The study's collection of clinical specimens spans most of the history of the HIV epidemic, from uninfected individuals of the early 1980s to long-term nonprogressors - people who remain healthy 10 years or more after becoming infected with HIV - today. Its size and longevity have uniquely positioned the MACS to answer questions that other studies could not easily approach.

"In its 15 years, the MACS has amassed a wealth of clinical information and biological specimens," says Jack Killen, M.D., director of the Division of AIDS at NIAID. "Together with the huge databases to which they are linked, these specimens provide the general scientific community with an invaluable research resource for multidisciplinary investigation." The availability of MACS specimens has led to research collaborations with more than 100 investigators outside the MACS.

The idea for the MACS evolved in the early 1980s, before anyone k
'"/>

Contact: John Bowersox
jbowersox@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
20-Apr-1999


Page: 1 2 3 4

Related medicine news :

1. NIAID initiates trial of experimental avian flu vaccine
2. NIAID seeks applicants to lead clinical trials units for revamped HIV/AIDS networks
3. NIAID begins enrolling volunteers for novel HIV vaccine study
4. NIAID-sponsored clinical trial aims to boost flu vaccine supply
5. NIAID seeks applicants to lead revamped HIV/AIDS clinical trials networks
6. NIAID launches influenza genome sequencing project
7. NIAID launches program to improve medical tools against emerging infectious diseases
8. NIAID forms network to tackle potentially fatal reaction to smallpox vaccine
9. NIAID rotavirus vaccine licensed for commercialization
10. Second NIAID SARS vaccine candidate helps mice fend off SARS
11. NIAID vaccine protects against SARS virus infection in mice

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: NIAID Renews Funding For Multicenter AIDS Cohort Study

(Date:5/21/2013)... Boston, Mass.By studying the roles two proteins, thrombospondin-1 ... trans-Atlantic research team has identified a five-amino acid ... in mouse models of prostate, breast and lung ... could potentially block metastasis in a variety of ... Randolph Watnick, PhD, at Boston Children,s Hospital, Vivek ...
(Date:5/21/2013)... May 21, 2013 The nation’s first ... is nearing its conclusion in Washington state court, ... closing statements yesterday, an attorney for the Plaintiffs compared ... wanted to tie sales and services for its customers. ... to keep control of surgeons, to keep control of ...
(Date:5/21/2013)... A new study appearing in the ... stem cells harvested from fat (adipose) are more potent ... modulate the body’s immune system. , The finding ... as adipose tissue-derived stem cells (AT-SCs) are far more ... marrow and can be collected from waste material from ...
(Date:5/21/2013)... TUESDAY, May 21 (HealthDay News) -- Less is more ... severe bouts of chronic obstructive pulmonary disease (COPD), according ... with prednisone to treat COPD flare-ups was as good ... for adverse side effects, they said. "We wanted ... not less effective than 14 days," said lead researcher ...
(Date:5/21/2013)... of Iowa,s vice president for research and economic ... computing, the next generation of supercomputers designed to ... the human mind. , Daniel Reed will appear ... the House Subcommittee on Energy, titled, "America,s Next ... at 10 a.m. in Room 2318 of the ...
Breaking Medicine News(10 mins):Health News:Changing cancer's environment to halt its spread 2Health News:Changing cancer's environment to halt its spread 3Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 2Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 3Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 4Health News:Stem Cells from Fat Outperform Those from Bone Marrow in Fighting Disease 2Health News:Stem Cells from Fat Outperform Those from Bone Marrow in Fighting Disease 3Health News:COPD Patients May Do Fine With Shorter Course of Steroids 2Health News:COPD Patients May Do Fine With Shorter Course of Steroids 3Health News:Iowa VP for Research addresses next-generation supercomputers at congressional hearing 2
(Date:5/21/2013)... May 21, 2013 On its tenth ... product developments at the Special Libraries Association PHTD meeting in ... focus on product literature databases and workflow solutions for the ... said founding director Nigel Johnson . "At ... to our clients and what better forum to announce them ...
(Date:5/21/2013)... 21, 2013 /PRNewswire-iReach/ -- The 2013 Pharma ChemOutsourcing Show ... the greatest number of "Emerging" small molecule biotech ... Mark Alexay .  "No one saw this ... year.  The show,s still 4 months away and we ... a big surprise and great news for attendees". Thecurrent ...
(Date:5/21/2013)... 2013  Decision Resources, one of the ... pharmaceutical and healthcare issues, finds that the ... efficacy endpoints, including overall survival and time ... over surveyed U.S. and European oncologists, prescribing ... breast cancer. The two novel emerging therapies ...
Breaking Medicine Technology:Pi2 Solutions' 10th Anniversary Heralds New Corporate Image as Platinum Sponsor of SLA PHT Meeting in Philadelphia 2Pi2 Solutions' 10th Anniversary Heralds New Corporate Image as Platinum Sponsor of SLA PHT Meeting in Philadelphia 3Emerging Pharma at ChemOutsourcing 2013 in Record Numbers for Upcoming September Show 2Thought-Leader Opinion and Clinical Data Indicate that Emerging Agents from Two Drug Classes Have Efficacy Advantages Over Currently Used Therapies for HR-Positive, HER2-Negative Breast Cancer 2
Cached News: